Status:
COMPLETED
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
Lead Sponsor:
Galderma R&D
Conditions:
Psoriasis
Eligibility:
All Genders
18-80 years
Brief Summary
Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.
Detailed Description
Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in the target plaq...
Eligibility Criteria
Inclusion
- Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with a target plaque severity (TPS) of moderate to severe
- At least 1 target site (not on the palms or soles of the feet) with a TPS rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having well-circumscribed margins, and at least 1 cm in diameter
- History of stable plaque psoriasis of greater than or equal to 3 months
Exclusion
- Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis
- Psoriatic arthritis that was not stable or might have required a change in medication during the 4-week study period
- Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
2488 Patients enrolled
Trial Details
Trial ID
NCT00437216
Start Date
February 1 2006
End Date
July 1 2006
Last Update
July 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DHC Dimensional HealthCare, Inc. (Clinical Research Organization)
Cedar Knolls, New Jersey, United States, 76117